Chiesi has announced the largest acquisition in its 90-year history, agreeing to purchase KalVista Pharmaceuticals for approximately $1.9 billion. This... Read more
Category: Uncategorized
BMS: High Expectations for Next-Gen Blockbusters Amid Patent Cliff Hurdles
Bristol Myers Squibb (BMS) is generating investor buzz with its late-stage pipeline despite a modest Q1 2026 financial performance. The... Read more
Eli Lilly Lifts 2026 Guidance Following Dominant Q1 Performance
Eli Lilly started the 2026 fiscal year with record-breaking numbers, driven by surging demand for its obesity and diabetes portfolio.... Read more
Merck’s $6.7B Acquisition of Terns: Strategic Diligence Saves $1B
During its Q1 2026 earnings call, Merck & Co. executives detailed the strategic rationale behind the acquisition of Terns Pharmaceuticals,... Read more
Biotech IPO Surge: Hemab and Seaport Raise Combined $556M
The biotech sector's financial momentum continues to accelerate as Hemab Therapeutics and Seaport Therapeutics made their Wall Street debuts in... Read more
Proposed Enhanced Security for Mandatory Psychiatric Treatment: 3-Layer Doors and 24/7 Surveillance
The Ministry of Health has recently proposed a draft Decree aimed at strengthening the management of individuals under mandatory psychiatric... Read more
Healthcare Report for April 30 – May 1 Holiday: Stable Operations and Full-Scale Emergency Readiness
During the first 24 hours of the 2026 holiday period, healthcare facilities nationwide strictly adhered to emergency standing orders, ensuring... Read more
Major healthcare reform: Decentralization and streamlining procedures starting July 2026
The Government has issued Resolution No. 21/2026/NQ-CP, signaling a major shift in healthcare administration by reducing administrative barriers and optimizing... Read more
Nadyphar Sets Revenue Targets and Finalizes Senior Leadership Transition
Nadyphar Pharmaceutical JSC (UPCoM: NDP) recently held its 2026 Annual General Meeting of Shareholders, outlining a strategic revenue goal of... Read more









